Please login to the form below
Thyroid eye disease
This page shows the latest Thyroid eye disease news and features for those working in and with pharma, biotech and healthcare.
Horizon bolsters rare disease portfolio with $3bn Viela Bio acquisition
In January 2020, Horizon received FDA approval for its thyroid eye disease (TED) treatment Tepazza. ... Tepezza is the first medicine approved for the rare autoimmune disease, which can cause eye bulging, facial disfigurement and vision loss.
Latest news
-
FDA approves Horizon's thyroid eye disease drug ahead of schedule
First FDA-approved treatment for rare autoimmune condition. Horizon Therapeutics has won a speedy approval for its thyroid eye disease (TED) treatment Tepezza in the US. . ... We believe teprotumumab may impact underlying mechanisms of fibrosis and
-
Horizon looks bright as FDA panel backs eye drug teprotumumab
thyroid eye disease (TED). ... It’s most often caused by an overactive thyroid gland (Graves’ disease), and occurs in around one in four people with that condition.
-
Horizon sunny as thyroid eye disease drug hits the mark
New treatment helps lessen eye bulging. Horizon Pharma shares rose strongly after it reported a positive phase 3 trial of teprotumumab for the treatment of active thyroid eye disease (TED), which ... If approved, teprotumumab would give physicians the
-
FDA awards $19m in rare disease grants
One study – to investigate neonatal respiratory distress syndrome – received $1.4m; one involving thyroid eye disease received $1.2m; and three more received less than $1m.
FDA approves Horizon's thyroid eye disease drug ahead of schedule
Horizon looks bright as FDA panel backs eye drug teprotumumab
FDA awards $19m in rare disease grants
More from news
Approximately 2 fully matching, plus 3 partially matching documents found.
Latest Intelligence
-
European biotech: a new generation of leaders emerges
43% complete responses indicating the disease had disappeared entirely. ... Another of its partners, Horizon Therapeutics recently submitted to the FDA the Genmab-developed teprotumumab for the treatment of active thyroid eye disease.
European biotech: a new generation of leaders emerges
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Digital Project Director, Healthcare Marketing Agency patient fo...
-
Highly competitive salary
- Senior Consultant, Pricing & Market Access Consultancy, circ...
-
circa £100K package
- Project Director, Healthcare Marketing Agency patient focus Lond...
-
Highly competitive salary
-
Digital account director
-
Competitive
- Account Manager - Healthcare Consultancy
-
Salary depending on experience
- Principal/ Senior/ Medical Writer – Global Med Ed and Comms Agen...
-
Highly competitive salary
-
Events Executive
-
Depending on Experience
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- Mixing AZ and Pfizer COVID-19 vaccines increases antibody levels
- AZ publishes new real-world safety data for COVID-19 vaccine Vaxzevria
- The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
- CHMP rejects Kyowa Kirin’s Parkinson’s disease drug
- Google’s DeepMind opens ‘breakthrough’ protein database to the world
- Distracted boyfriend: the secret of a successful long-distance relationship
- Merck & Co’s sales bounce back in ‘ongoing recovery from COVID-19’
- Lilly and Kumquat Biosciences link up in $2bn-plus immuno-oncology deal
- Michael J. Fox Foundation and IBM reveal new AI model for Parkinson’s disease
- BMS’ Q2 results beat expectations with strong performance across core therapy areas
- Amanda Pritchard becomes NHS England’s first female chief executive
- Roche engaged in talks with FDA for Alzheimer’s drug candidate
- Vertex gains FDA fast track designation for diabetes stem cell therapy
- Onyx Health Launch Creative Studio After Record Year
- Pfizer and Arvinas announce $1bn deal for investigational oral protein degrader
- Roche appoints Philip Atkinson to new global role
- AZ’s comeback drug cediranib stumbles in phase 3 trial
PMHub
Frontera Group
A leading global patient-activation group - comprising of a digital insight consultancy, creative activation agency. Our foundations lie in behavioural...
Latest intelligence
- Top 10 ways to leverage the Impetus InSite Platform® to (virtually) launch your brand
- The Impetus InSite Platform® can be used to facilitate virtual and hybrid engagement at all stages of the product lifecycle. Here, we share 10 of the most popular ways to...
- Employee wellbeing in creative agencies: three tips to get you started
- Paul Hutchings, founder of fox&cat, and new friend, Welfy, a workplace wellbeing training firm, discuss the importance of collaboration...
- Managing unhelpful pressure in your creative agency: the human approach
- Paul Hutchings, founder of fox&cat, answers the questions: what does it mean to be human in 2021? Are we putting ourselves under too much pressure?...
